Akero Therapeutics, Inc.
- Tickers
- None listed
- Headquarters
- Not recorded
- SEC CIK
- 0001744659
- Website
- Not recorded
Closing prices
This company has no stock ticker on record, so there are no prices to show.
Drugs
| Drug | Indications | Phase | Next catalyst | CT-VCA | Trials |
|---|---|---|---|---|---|
| Efruxifermin | MASH - Metabolic Dysfunction-Associated Steatohepatitis; MASH With Fibrosis; NAFLD/MASLD; NASH - Nonalcoholic Steatohepatitis; NASH With Fibrosis | Phase 3 | None scheduled | 3 |
FDA-approved applications
No Drugs@FDA application has a sponsor name that matches this company.
Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.
Catalysts
No catalysts yet. Editors add each date together with its source.
Deals
No approved deals involve this company yet.
Reported fundamentals (SEC XBRL)
| Metric | Reported value | Period | Filing |
|---|---|---|---|
| Revenue | Not reported in XBRL filings since 2015 | ||
| Net income (loss) | −81,566,000 USD | 1 Jul 2025 to 30 Sep 2025 FY2025 Q3 | 10-Q for Net income (loss) on sec.gov (opens in a new tab)Filed |
| Research and development expense | 78,883,000 USD | 1 Jul 2025 to 30 Sep 2025 FY2025 Q3 | 10-Q for Research and development expense on sec.gov (opens in a new tab)Filed |
| Operating expenses | Not reported in XBRL filings since 2015 | ||
| Cash and cash equivalents | 176,032,000 USD | At 30 Sep 2025 FY2025 Q3 | 10-Q for Cash and cash equivalents on sec.gov (opens in a new tab)Filed |
| Short-term investments and marketable securities | 561,794,000 USD | At 30 Sep 2025 FY2025 Q3 | 10-Q for Short-term investments and marketable securities on sec.gov (opens in a new tab)Filed |
| Total liabilities | 47,940,000 USD | At 30 Sep 2025 FY2025 Q3 | 10-Q for Total liabilities on sec.gov (opens in a new tab)Filed |
| Stockholders' equity | 957,637,000 USD | At 30 Sep 2025 FY2025 Q3 | 10-Q for Stockholders' equity on sec.gov (opens in a new tab)Filed |
| Common shares outstanding (cover page) | 82,316,179 shares | At 3 Nov 2025 FY2025 Q3 | 10-Q for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed |
History
| Period | Reported value | Filing |
|---|---|---|
| 1 Jul 2025 to 30 Sep 2025 FY2025 Q3 | −81,566,000 USD | 10-Q filed 7 Nov 2025 on sec.gov (opens in a new tab)Filed |
| 1 Apr 2025 to 30 Jun 2025 FY2025 Q3 | −70,505,000 USD | 10-Q filed 7 Nov 2025 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2025 to 31 Mar 2025 FY2025 Q3 | −70,725,000 USD | 10-Q filed 7 Nov 2025 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2024 to 31 Dec 2024 FY2025 Q3 | −252,060,000 USD | 10-Q filed 7 Nov 2025 on sec.gov (opens in a new tab)Filed |
| 1 Jul 2024 to 30 Sep 2024 FY2025 Q3 | −72,705,000 USD | 10-Q filed 7 Nov 2025 on sec.gov (opens in a new tab)Filed |
| 1 Apr 2024 to 30 Jun 2024 FY2025 Q3 | −55,987,000 USD | 10-Q filed 7 Nov 2025 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2024 to 31 Mar 2024 FY2025 Q3 | −53,344,000 USD | 10-Q filed 7 Nov 2025 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2023 to 31 Dec 2023 FY2025 Q3 | −151,759,000 USD | 10-Q filed 7 Nov 2025 on sec.gov (opens in a new tab)Filed |
The newest 12 periods of each metric are listed; older ones are on sec.gov.
Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.
Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-25 · read
SEC filings
Source: SEC EDGAR. Each row links to the filing on sec.gov.
Related news
No recent headlines mention this company.
Insider transactions
All rows for Akero Therapeutics, Inc. on Insider TradesLast 90 days of Form 4 filings, from 4 Aug 2026 (US Eastern dates).
- Buys code P
- None in this period
- Sells code S
- None in this period
- Other all other codes
- None in this period
Last transaction:
Insider filings are public records and are not a recommendation. Source: SEC EDGAR.
Sources
- Editor source (opens in a new tab) Licence: editorial. Entered by an editor, not fetched automatically
- SEC EDGAR submissions (opens in a new tab) Licence: public-domain. Fetched
Nothing on this page is investment advice.